Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Figure out How to Remain Persuaded During Your Internet based Degree Program - 2'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- 3Don't fall for it: These common tourist scams in Rome are easy to avoid if you know what you're looking for
- 4Step by step instructions to Choose the Right Auto Crash Legal counselor for Your Case
- 5Story of ‘first Black Briton’ rewritten by advances in ancient DNA technology
- The Development of Shipping: Controlling Towards a More Associated Future
- Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- The Main 15 Applications for Efficiency and Association
- Instructions to Pick the Ideal Pre-assembled Home for Your Necessities
- He walked on the moon in 1972. This is his advice for the Artemis II astronauts.
- Warnings rise for U.S. as severe flu strain causes outbreaks in Canada, U.K.
- 'Stranger Things' Season 5: What's going on with Will Byers? That shocking Volume 1 plot twist, explained.
- RFK Jr.'s diet guidelines emphasize red meat, full-fat dairy. How healthy are they?
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
